Naomi Kresge

La exitosa inyección Ozempic de Novo Nordisk A/S se relacionó con un mayor riesgo de padecer una forma rara de pérdida de visión en un estudio que respalda una investigación de la Universidad de Harvard publicado este año.

Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.

The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between Novo Nordisk A/S’s blockbuster shot Ozempic and a rare form of vision loss.

Novo Nordisk A/S 's shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker's ability to compete in the exploding market for weight-loss drugs.

Novo Nordisk A/S’s experimental shot CagriSema helped patients lose an average of 22.7% of their weight in a study that will help determine whether the drugmaker can continue to dominate the obesity drug market it helped establish.

In This Article NVO LLY (Bloomberg) -- Novo Nordisk A/S's shares fell by the most on record after patients

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados decepcionantes de una de las drogas con las que esperaba superar a su rival Eli Lilly & Co. en el mercado de los medicamentos contra la obesidad.

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs.

In This Article NVO LLY (Bloomberg) -- Novo Nordisk A/S's failure to meet its own bar for success on a

Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing $1.2 billion to build a new factory